The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Ascvd
-
Age: Between 40 - 99 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Adults age = 40 years and able to provide written informed consent
- Participants who are one of the following:
- Hospitalization for a clinical atherosclerotic cardiovascular disease (ASCVD) event
- Coronary or peripheral revascularization including percutaneous or surgical revascularization
- Participants with one of the following:
- Low-density lipoprotein (LDL) = 70 mg/dL (1.81 mmol/L)
- Newly started on Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) after the index hospitalization/procedure and prior to enrollment
- Participants with one of the following:
- The presence of an additional ASCVD event
- Has one or more high-risk conditions as per the investigator
- Participants who will planned follow-up within the health system.
You may not be eligible for this study if the following are true:
-
- Subject are unable or unwilling to provide informed consent
- Subjects who lack of phone or email for contact
- Subjects who has evidence of end stage renal disease (ESRD) or stage 5 CKD
- Subjects with anticipated life expectancy less than 6 months
- Subjects on a PCSK9i prior to their qualifying event
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.